The PD-1/PD-L1 or PD-L2 signalling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production.
PD-1 [CD279]/PD-L1 [CD274] Pathway
![PD-1 [CD279]/PD-L1 [CD274] Pathway](https://www.caltagmedsystems.co.uk/information/wp-content/uploads/pd-1-600x400px-600x300.png "PD-1 [CD279]/PD-L1 [CD274] Pathway")
Nano Vaccines Induce T Cell Immunity and Control of Tumour Growth
Using nanoparticle technology in making vaccines for infectious diseases/cancer is advancing & enhances the immunogenicity of some vaccine candidates.
Is your drug candidate able to reverse the T Cell Exhaustion-like state in MBL’s in vitro functional screening assay?
The process of T cell exhaustion & how it can be harnessed for immuno-oncology drug discovery and for immune checkpoint screening of drug candidates.
T Cell Immune Checkpoints for Immuno-Oncology Research
AdipoGen Life Sciences offers a broad panel of immune checkpoint reagents, including recombinant proteins, antibodies and ELISA Kits.